Discloses use of an isolated anti-Epidermal Growth Factor Receptor (EGFR) IgG1 antibody conjugated to a cytotoxic agent, in the preparation of a medicament for treating cancer in a subject, wherein said antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 164, and comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 166, and wherein said antibody further comprises a kappa light chain constant region, wherein the sequences are as defined in the complete specification.